Which diseases can be treated by Venetoclax/Venetoclax (Vekela) and its efficacy evaluation

Venetoclax (Venetoclax, also known as venetoclax) is a highly selective BCL-2 inhibitor that works by promoting tumor cell apoptosis. BCL-2 is an anti-apoptotic protein that is highly expressed in a variety of malignant hematological tumors, making it difficult for cancer cells to be eliminated naturally. Venaclat was initially approved in the United States for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Since then, its indications have gradually expanded, and it has become one of the important drugs in the treatment of various hematological tumors.

In the fields of CLL and SLL, venetoclax alone or in combination with rituximab (Rituximab) has shown excellent response rates in multiple phase III clinical studies, and some patients can even achieve deep molecular remission. Compared with traditional chemotherapy, venetoclax can significantly extend progression-free survival (PFS) and reduce the risk of recurrence. For elderly patients who cannot tolerate chemotherapy or those with high-risk genetic backgrounds, venetoclax provides a safer and more effective treatment option.

In acute myeloid leukemia (AML), venetoclax combined with low-intensity chemotherapy (such as azacitidine or decitabine) has become one of the first-line standard regimens for elderly or patients who are not suitable for intensive chemotherapy, significantly improving the complete response rate and overall survival. In addition, venetoclax is also undergoing clinical research in multiple myeloma, non-Hodgkin lymphoma and some solid tumors, especially in patient groups with high expression of BCL-2 or specific gene mutations, and has initially shown positive effects.

In real-world treatment, venetoclax demonstrated good tolerability and durable efficacy. Its oral administration method improves patient compliance, and programs combined with targeted drugs or immunotherapy are continuously expanding the scope of indications. In the future, with the development of molecular detection technology and through precise screening of patient populations, venetoclax is expected to exert greater therapeutic potential in more hematological tumors and certain solid tumors, becoming an important part of targeted therapy.

Reference materials:https://www.drugs.com/